SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Lindqvist Olle)
 

Search: WFRF:(Lindqvist Olle) > (2005-2009) > Comparable morning ...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Zetterström, Olle,1940-Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Allergicentrum,Allergicentrum US (author)

Comparable morning versus evening administration of once-daily mometasone furoate dry powder inhaler

  • Article/chapterEnglish2008

Publisher, publication year, extent ...

  • Elsevier BV,2008
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-43424
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-43424URI
  • https://doi.org/10.1016/j.rmed.2008.04.024DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:117676142URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Background: The control of daytime and nighttime symptoms is an important measure of effectiveness of asthma therapy, especially, when administered once-daily. Objective: To evaluate the efficacy of evening and morning administrations of mometasone furoate administered via a dry powder inhaler (MF-DPI) 400 μg once-daily (QD) to show equivalence. Methods: Open-label, randomized, parallel-group study in adult patients with mild to moderate asthma with a ≥3-month history of ICS use. Patients received MF-DPI 400 μg QD either in the morning (AM) or evening (PM) for 12 weeks. The primary measure was the change in asthma symptoms from baseline to week 12. Secondary outcomes included response to treatment, adherence, inhaler device evaluation, use of rescue medication, urinary cortisol levels, and differential white blood cell count. Results: A total of 1537 patients were randomized, the efficacy population comprised 543 and 479 patients in the MF-DPI QD morning and evening groups, respectively. Mean improvements from baseline in daytime symptom scores at week 12 with morning and evening administration of MF-DPI 400 μg were -0.11 ± 0.59 and -0.12 ± 0.68, respectively (95% CI, -0.095 to 0.061) and the corresponding improvements in nighttime symptom scores were -0.08 ± 0.59 and -0.07 ± 0.50, respectively (95% CI, -0.067 to 0.068). Use of rescue medication was the same in both groups (1 puff/day). MF-DPI QD was well tolerated regardless of time of administration. Conclusions: This open-label study did not identify differences between morning and evening dosing of MF-DPI 400 μg QD. A better effect of evening dosing compared to morning dosing found in previous double-blind placebo-controlled studies could not be confirmed. © 2008 Elsevier Ltd. All rights reserved.

Subject headings and genre

  • MEDICINE
  • MEDICIN

Added entries (persons, corporate bodies, meetings, titles ...)

  • Dahl, R.Department of Respiratory Medicine Aarhus University Hospital, Denmark (author)
  • Lindqvist, A.Department of Medicine Helsinki University Central Hospital, Helsinki, Finland (author)
  • Olsson, P.Centre for Allergy Research Karolinska Institutet, Stockholm, Sweden (author)
  • Linköpings universitetHälsouniversitetet (creator_code:org_t)

Related titles

  • In:Respiratory Medicine: Elsevier BV102:10, s. 1406-14110954-61111532-3064

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Find more in SwePub

By the author/editor
Zetterström, Oll ...
Dahl, R.
Lindqvist, A.
Olsson, P.
Articles in the publication
Respiratory Medi ...
By the university
Linköping University
Karolinska Institutet

Search outside SwePub

Wikipedia about the author:
Olle_Zetterström
Zetterström, Olle,1940-
en

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view